A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer
Authors
Keywords
c-Met inhibitor, Tivantinib, ARQ 197, Gastric cancer, Phase II study
Journal
INVESTIGATIONAL NEW DRUGS
Volume 32, Issue 2, Pages 355-361
Publisher
Springer Nature
Online
2013-12-14
DOI
10.1007/s10637-013-0057-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MET amplification as a potential therapeutic target in gastric cancer
- (2015) Hisato Kawakami et al. Oncotarget
- The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors
- (2013) N. Yamamoto et al. ANNALS OF ONCOLOGY
- Tivantinib in hepatocellular carcinoma
- (2012) Jörg Trojan et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
- (2012) Jung Hun Kang et al. JOURNAL OF CLINICAL ONCOLOGY
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
- (2012) Armando Santoro et al. LANCET ONCOLOGY
- MET: a promising anticancer therapeutic target
- (2012) Solange Peters et al. Nature Reviews Clinical Oncology
- A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors
- (2011) L. S. Rosen et al. CLINICAL CANCER RESEARCH
- Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197
- (2011) Sudharshan Eathiraj et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
- (2011) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic Activation of theMETPathway and Prognosis of Patients With High-Risk, Radically Resected Gastric Cancer
- (2011) Francesco Graziano et al. JOURNAL OF CLINICAL ONCOLOGY
- METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
- (2011) Jochen K. Lennerz et al. JOURNAL OF CLINICAL ONCOLOGY
- Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence
- (2011) D. V. T. Catenacci et al. Cancer Discovery
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity
- (2010) N. Munshi et al. MOLECULAR CANCER THERAPEUTICS
- Is there a role for second-line chemotherapy in advanced gastric cancer?
- (2009) Robert Wesolowski et al. LANCET ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started